Intensive Glucose Lowering and Its Effects on Vascular Events and Death According to Age at Diagnosis and Duration of Diabetes: The ADVANCE Trial
Primary result · Major macrovascular and microvascular events, by age at diagnosis and diabetes durationResult — go to the resultHazard ratio 0.90 95% CI 0.82–0.98Authors' conclusion
Intensive glucose lowering may be recommended irrespective of age at diagnosis or diabetes duration.
Study context
- Population
- ADVANCE participants with diabetes, subgroups by age at diagnosis (≤50, >50–60, >60 years) and diabetes duration (≤5, >5–10, >10 years)
- Participants
- 11,138 participants
- Comparison
- More vs less glucose lowering
- Primary endpoint
- Composite of:
- Major macrovascular
- Microvascular events
Methodological detailssubgroup analysis by age at diabetes diagnosis and diabetes duration
- Subgroup analysis by age at diabetes diagnosis and diabetes duration
Primary result
As reported in the abstract
Major macrovascular and microvascular events, by age at diagnosis and diabetes duration
Hazard ratio
0.90
95% CI 0.82–0.98
Intensive glucose loweringvs Less glucose lowering
HR 0.90 (95% CI 0.82–0.98)
Further findings
All-cause death, CV death and components of major vascular events
- Similar consistent treatment effects across subgroups
Original publication
Intensive Glucose Lowering and Its Effects on Vascular Events and Death According to Age at Diagnosis and Duration of Diabetes: The ADVANCE Trial. Diabetes Care. Published 11 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →